Numinus Wellness Provides Corporate Update

Executive Summary

• Numinus Wellness Inc. reports completion of its strategic transformation, focusing on clinical trial sites and practitioner‑training platforms.
• The company is working to complete its 2025 audit to lift a cease‑trade order (CTO) and address a Toronto Stock Exchange delisting review.
• Management indicates it is evaluating financing options, strategic partnerships and possible M&A to strengthen the balance sheet after audit completion.

Key Details

• Strategic Transformation: Sale of U.S. wellness clinics completed; wind‑down of non‑operating subsidiaries; CFO transition in early 2025.
• Operating Segments:
• Clinical trial site network – supported >20 psychedelic drug development studies; Cedar Clinical Research remains active.
• Practitioner training platform – >2,500 practitioners trained to date, including >800 research therapists for clinical trials; expanded program in 2025 to serve drug‑development sponsors.
• Regulatory & Listing Status:
• 2025 audit (year ended Aug 31 2025) is ongoing; filing of audited financial statements will enable removal of the BCSC cease‑trade order and response to TSX delisting review initiated Nov 2025.
• TSX review focuses on financial condition, operating results, divestiture of substantial operations, disclosure compliance, and change of business.
• Annual General Meeting: AGM for year ended Aug 31 2025 not held by Feb 28 2026 deadline; meeting to be scheduled after audit completion and progress on CTO revocation.
• Outlook & Strategic Initiatives: Company is evaluating financing opportunities, strategic partnerships, new business initiatives, and potential mergers or acquisitions to bolster its balance sheet and support growth.
• Forward‑Looking Statements: All forward‑looking remarks are subject to risks and uncertainties; actual results may differ materially.

Notable Quotes

(No direct quotes were provided in the release.)